News

The company will use the money for advancing its two preclinical candidates – VA106483 for nocturia and VA111913 – as a treatment for dysmenorrhoea. The results from Phase

Chugai has licensed marketing and development rights for CSG452 to Roche in January 2007 as a treatment for type II diabetes. Roche’s decision was backed by the priority

The FDA’s decision was based on its inspection which it has conducted in February 2011 and identified significant violation of current good manufacturing practices at the plant, reported

APP Pharma‘s Nafcillin for injection, which is indicated for the treatment of infections caused by penicillinase-producing staphylococci, is the generic version of GlaxoSmithKline (GSK) marketed drug Nallpen and

The agreement covers novel classes of antibiotics resulting from Rib-X’s RX-04 program which have demonstrated antibacterial activity against Gram-negative and Gram-positive pathogens. As per the terms of the

The tie up allows the companies to evaluate the effectiveness of sclerostin antibody on the loss of bone linked with space flight in mice. The sclerostin antibody inhibits

The products of Rowa are intended for the management of medication and retrieval of pre-packaged pharmaceutical inventory. The Rowa products secure and automate large volumes of medications and

The distributing and licensing deal was inked between an affiliate of Sanofi and Theratechnologies on 6 December 2010. Under the agreement, Sanofi has been licensed commercialization rights for

The three products – Adrenalin (epinephrine injection, USP), Coly-Mycin M Parenteral (colistimethate sodium, USP) and Pitocin (oxytocin injection, USP synthetic) – are commonly used in acute care clinical